Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133401 | 1.00 | KMT2A (0.71) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL3243431 | 0.92 | KMT2A (0.69) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL28693694 | 0.92 | KMT2A (0.69) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL30167982 | 0.89 | KMT2A (0.80) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL9803295 | 0.89 | KMT2A (0.80) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL10787479 | 0.89 | KMT2A (0.80) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL8517907 | 0.88 | KMT2A (0.73) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL4509654 | 0.87 | KMT2A (0.77) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL1572959 | 0.86 | KMT2A (0.71) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL5009881 | 0.86 | NR4A2 (0.65) | KMT2ANR4A2AKR1C3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-3551631-B9 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2025-02-26 | — | — | EP | disclosed |
| EP-4494705-A2 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2025-01-22 | — | — | EP | disclosed |
| EP-3551631-B1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-11-13 | — | — | EP | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| CN-113164459-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| EP-3551631-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | The University of Sydney (AU) | 2019-10-16 | — | — | EP | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2018107216-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | KMT2A 300/4885NR4A2 3758/4885AKR1C3 192/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | KMT2A 3729/4885NR4A2 1245/4885AKR1C3 640/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMT2A 1069/4885NR4A2 1508/4885AKR1C3 1105/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KMT2A 1069/4885NR4A2 1508/4885AKR1C3 1105/4885 |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | KMT2A 300/4885NR4A2 3758/4885AKR1C3 192/4885 |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | KMT2A 300/4885NR4A2 3758/4885AKR1C3 192/4885 |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | OXTR, AVPR1B, AVPR1A | KMT2A 4523/4885NR4A2 1005/4885AKR1C3 2109/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KMT2A 1069/4885NR4A2 1508/4885AKR1C3 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.